Anti-ulcer agents. Recommendations and medical references;Anti-ulcereux. Recommandations et references medicales

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 11, 1996, Pages 991-1008

  Colin, Raymond ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIULCER AGENT; CIMETIDINE; FAMOTIDINE; INIPROMP; LANSOPRAZOLE; MISOPROSTOL; NIZATIDINE; OMEPRAZOLE; PANTEC; PANTOPRAZOLE; PRESDA; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE; UNCLASSIFIED DRUG;

DYSPEPSIA; ESOPHAGITIS; HELICOBACTER PYLORI; HUMAN; REVIEW; STOMACH ULCER;

EID: 16144364284     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Howden CW. Appropriate acid suppression in the treatment of acid-related conditions. Pharmacol Ther 1994; 63: 123-34.
2. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
3. Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, et al. Variability in individual response to various doses of omeprazole: implications for antiulcer therapy. Dig Dis Sci 1994; 39: 161-8.
4. McCarthy DM. Sucralfate. N Engl J Med 1991; 325: 1017-25.
5. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992; 327: 1575-80.
6. Jansen JBMJ, Klinkenberg-Knol EC, Meuwissen SGM, de Bruijne JW, Festen HPM, Snel P et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990; 99: 621-8.
7. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid. Ann Intern Med 1994; 121: 232-3.
8. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51(Suppl 1): 82-92.
9. Sontag SJ. Gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 293-312.
10. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer. A meta-analysis to define optimal dosing wilh antisecretory drugs. Gut 1987; 28: 1120-7.
11. Mclsaac RL, Dixon JS, Mills JG, Wood JR. Ranitidine in the treatment of duodenal ulcer disease. Relationship between antisecretory effect and ulcer healing rate. Aliment Pharmacol Ther 1991; 5: 227-43.
12. Morgan DG, Burget DW, Howden CW, Jacobson K, Wong D, Hewak J, et al. Rates of duodenal ulcer (DU) healing by drug classes: a meta-analysis. Gastroenterology 1993; 104: A150.
13. Spencer CM, Faulds D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30.
14. McTavish D, Buckley MMT, Heel RC. Omeprazole. An update review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138-70.
15. Bamberg P, Caswell CM, Frame MH, Lam SK, Wong ECK. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol 1992; 7: 577-85.
16. Wilde MI, McTavish D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
17. Misra SC, Dasarathy S, Sharma MP. Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. Aliment Pharmacol Ther 1993; 7: 443-9.
18. Mulder CJJ, Schipper DL. Omeprazole and ranitidine in duodenal ulcer healing. Analysis of comparative clinical trials. Scand J Gastroenterol Suppl 1990; 178: 62-6.
19. Judmaier G, Koelz HR. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. The Pantoprazole-Duodenal Ulcer Study Group. Aliment Pharmacol Ther 1994; 8: 81-6.
20. Hawkey CJ, Long RG, Bardhan KD, Wormsley KG, Cochran KM, Christian J, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993; 34: 1458-62.
21. McFarland RJ, Bateson MC, Green JRB, O'Donoghue DP, Dronfield MW, Keeling PWN, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98: 278-83.
22. Battaglia G, Di Mario F, Vigneri S, Dal Santo P, Pilotto A, Mazzacca G, et al. Peptic ulcer in the elderly. A double-blind, short-term study comparing nizatidine 300mg with ranitidine 300mg. Aliment Pharmacol Ther 1993; 7: 643-8.
23. Garcia-Paredes J, Diaz Rubio M, Llenas F, Taxonera C, Pardo L. Comparison of sucralfate and ranitidine in the treatment of duodenal ulcers. Am J Med 1991; 91(Suppl 2A): 64S-7S.
24. Lartigue S, Corrion F, Bernades P, Bonfils S, Chevalier T, Laverdant C, et al. Effet de l'enprostil sur la cicatrisation et la récidive des ulcères duodénaux. Comparaison à la ranitidine. Gastroenterol Clin Biol 1994; 18: 617-22.
25. Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: a multicentre trial. A Cooperative Study Group. Gut 1990; 31: 653-6.
26. Bergmann JF, Barbier JP, Abitbol V, Hamelin B. Facteurs pronostiques de la rapidité de cicatrisation de l'ulcère duodénal. Essai contrôlé oméprazole versus ranitidine. Presse Med 1995; 24: 559-62.
27. Okada M, Yao T, Maeda K, Yamamoto T, Saigenji K, Okada Y, et al. Predictors of duodenal ulcer healing during treatment with cimetidine. Gut 1990; 31: 758-62.
28. Reynolds JC, Schoen RE, Maislin G, Zangari GG. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 1994; 89: 571-80.
29. Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment. Lancet 1988; 1: 1147-9.
30. Graham DY, Colon-Pagan J, Morse RS, Johnson TL, Walsh JH, McCullough AJ, et al. Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group. Gastroenterology 1992; 102: 1289-94.
31. Mignon M, Ruszniewski P, Pappo M, Alberola B, Georges D. Traitement des poussées ou traitement préventif des récidives dans la maladie ulcéreuse duodénale? Etude contrôlée en double aveugle d'une prise quotidienne de ranitidine 150mg pendant un an. Groupe d'Etude de la Maladie Ulcéreuse Duodénale (GEMUD). Gastroenterol Clin Biol 1990; 14: 732-8.
32. Korman MG, Hansky J, Eaves ER, Schmidt GT. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871-4.
33. Paoluzi P, Pallone F, Zaccardelli E, Ripoli F, Marcheggiano A, Carratu R. Outcome of ulcer-associated duodenitis after short-term medical treatment. Dig Dis Sci 1985; 30: 624-9.
34. Blum AL. Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. Digestion 1990; 47(Suppl 1): 3-10.
35. Bianchi Porro G, Corinaldesi R, Lazzaroni M, Barbara L, Capurso L, Paoluzi P, et al. Long term treatment with omeprazole 20mg three days a week or 10mg daily in the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1994; 8: 541-8.
36. Lauritsen K, Andersen BN, Laursen LS, Hansen J, Havelund T, Eriksen J, et al. Omeprazole 20mg three days a week and 10mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology 1991; 100: 663-9.
37. Dobrilla G, Vallaperta P, Amplatz S. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment. A pooled estimate of controlled clinical trials. Gut 1988; 29: 181-7.
38. Palmer RH, Frank WO, Karlstadt R. Maintenance therapy of duodenal ulcer with H2-receptor antagonists. A meta-analysis. Aliment Pharmacol Ther 1990; 4: 283-94.
39. Silvis SE. Final report on the United States multicenter trial comparing ranitidine to cimetidine as maintenance therapy following healing of duodenal ulcer. J Clin Gastroenterol 1985; 7: 482-7.
40. Kurata JH, Koch GG, Nogawa AN. Comparison of ranitidine and cimetidine ulcer maintenance therapy. J Clin Gastroenterol 1987; 9: 644-50.
41. McDougle AMA, Lancaster-Smith MJ, Higson DL. Ranitidine maintenance therapy in the prevention of duodenal ulceration. A comparison of 150mg at night with 300mg at night. Aliment Pharmacol Ther 1995; 9: 287-91.
42. Bianchi Porro G, Lazzaroni M, Barbara L, Corinaldesi R, Blasi A, Mangiameli A, et al. A controlled study of 20mg famotidine nocte vs 150mg ranitidine nocte for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1991; 5: 181-9.
43. Penston JG, Wormsley KG. Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3-29.
44. Bardhan KD, Morris P, Hinchliffe RFC, Saunders JHB, MacDougall BRD, Bold JM, et al. A comparison of low-dose maintenance treatment with enprostil against ranitidine in the prevention of duodenal ulcer recurrence. Aliment Pharmacol Ther 1989; 3: 489-97.
45. Goldin E, Karmeli F, Rachmilewitz D. Efficacy of misoprostol and ranitidine in the prevention of duodenal ulcer relapse and its correlation with endogenous gastric prostanoid synthesis. Aliment Pharmacol Ther 1991; 5: 173-80.
46. Pounder RE, Festen H, Korman M. The long-term management of duodenal ulceration using an H2-antagonist: symptomatic self-care compared with maintenance treatment. Aliment Pharmacol Ther 1992; 6: 315-25.
47. Penston J, Wormsley KG. Efficacy and safety of long-term maintenance therapy of duodenal ulcers. Scand J Gastroenterol 1989; 24: 1145-52.
48. Susi D, Neri M, Ballone E, Mezzetti A, Cuccurullo F. Five-year maintenance treatment with ranitidine. Effects on the natural history of duodenal ulcer disease. Am J Gastroenterol 1994; 89: 26-32.
49. Sontag S, Graham DY, Belsito A, Weiss J, Farley A, Grunt R, et al. Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med 1984; 311: 689-93.
50. Sonnenberg A, Muller-Lissner SA, Vogel E, Schmid P, Gonvers JJ, Peter P, et al. Predictors of duodenal ulcer healing and relapse. Gastroenterology 1981; 81: 1061-7.
51. Lee FI, Hardman M, Jaderberg ME. Maintenance treatment of duodenal ulceration. Ranitidine 300mg at night is better than 150mg in cigarette smokers. Gut 1991; 32: 151-3.
52. Penston JG, Wormsley KG. Nine years of maintenance treatment with ranitidine for patients with duodenal ulcer disease. Aliment Pharmacol Ther 1992; 6: 629-45.
53. Simon B, Schütz E, Müller P, Dixon JS. Long-term management of peptic ulcer disease with ranitidine in Germany. Aliment Pharmacol Ther 1994; 8: 135-7.
54. Susi D, Neri M. The natural history of duodenal ulcer disease is modified after discontinuing a five-year maintenance therapy with ranitidine. Gastroenterology 1991; 100: A170.
55. Penston JG, Dixon JS, Boyd EJS, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther 1993; 7: 259-65.
56. Walan A, Bianchi-Porro G, Hentschel E, Bardhan KD, Delattre M. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397-405.
57. Bardhan KD. Six years of continuous cimetidine treatment in peptic ulcer disease: efficacy and safety. Aliment Pharmacol Ther 1988; 2: 395-405.
58. Jensen DM, You S, Jensen ME, Kovacs TOG, Machicado GA, Frankl H, et al. Randomized controlled study of ranitidine maintenance for patients with a recent severe duodenal ulcer hemorrhage. Gastroenterology 1990; 98: A65.
59. Blasi A, Bianchi Porro G, Capurso L, Corinaldesi R, Dobrilla G, Speranza V, et al. The Italian Consensus Conference on duodenal ulcer treatment. Ital J Gastroenterol 1993; 25: 99-104.
60. Armstrong D, Arnold R, Classen M, Fischer M, Goebell H, Schepp W, et al. RUDER. A prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. Dig Dis Sci 1994; 39: 1425-33.
61. Blum AL, Arnold R, Classen M, Goebell H, Fischer M, Witzel L. RUDER. Prospective study of the risk factors for duodenal ulcer in 2109 patients. The RUDER Study Group (abstract). Gastroenterology 1990; 98: A22.
62. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33.
63. Howden CW, Burget DW, Wilkinson J, Hunt RH. A comparison of different drug classes with respect to rapidity of healing of gastric ulcer (GU). Gastroenterology 1993; 104: A105.
64. Howden CW, Burget DW, Hunt RH. A meta-analysis to predict gastric ulcer healing from acid suppression (abstract). Gastroenterology 1991; 100: A85.
65. Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69-75.
66. Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud JC, Dupas JL, et al. Treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial. Aliment Pharmacol Ther 1994; 8: 119-22.
67. Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994; 8: 215-20.
68. Bate CM, Wilkinson SP, Bradby GVH, Bateson MC, Hislop WS, Crowe JP, et al. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 1989; 30: 1323-8.
69. Hotz J, Plein K, Schönekäs H, Rose K. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Scand J Gastroenterol 1995; 30: 111-5.
70. Blum AL, Bethge H, Bode JC, Domschke W, Feurle G, Hackenberg K, et al. Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study. Gut 1990; 31: 825-30.
71. Houston LJ, Mills JG, Wood JR. Does co-prescription of sucralfate with ranitidine therapy enhance the healing of gastric ulcers? Am J Gastroenterol 1993; 88: 675-9.
72. Witzel L, Gütz H, Hüttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995; 9: 19-24.
73. Interdisciplinary Group for Ulcer Study. Long-term treatment of patients with gastric ulcer sucralfate versus ranitidine versus no treatment. An interim report at the end of year1of a 3-year multicenter, randomized study. Curr Ther Res 1994; 55: 1117-25.
74. Takemoto T, Namiki M, Ishikawa M, Tsuneoka K, Oshiba S, Kawai K, et al. Ranitidine and sucralfate as maintenance therapy for gastric ulcer disease: endoscopic control and assessment of scarring. Gut 1989; 30: 1692-7.
75. Battaglia G. Risk factors of relapse in gastric ulcer: a one-year, double-blind, comparative study of nizatidine versus placebo. Ital J Gastroenterol 1994; 26(Suppl1): 19-22.
76. Penston JG, Wormsley KG. Long-term maintenance treatment of gastric ulcers with ranitidine. Aliment Pharmacol Ther 1990; 4: 339-55.
77. Ettersperger L, Bouché O, Zeitoun P. Devenir à 5 ans de 286 cas consécutifs d'œsophagite érosive par reflux (OER). Gastroenterol Clin Biol 1994; 18: A115.
78. Kuster E, Ros E, Toledo-Pimentel V, Pujol A, Bordas JM, Grande L, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35: 8-14.
79. Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Müller-Lissner SA. Three year follow up of patients with gastro-oesophageal reflux disease. Gut 1992; 33: 1016-9.
80. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl 1): 59-67.
81. Colin Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl 1): 9-14.
82. Hunt RH. The relationship between the control of pH and healing symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl 1): 3-7.
83. Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 98(Suppl 1): 15-25.
84. Fuchs KH, DeMeester TR, Albertucci M. Specificity and sensitivity of objective diagnosis of gastroesophageal reflux disease. Surgery 1987; 102: 575-80.
85. Galmiche JP, Scarpignato C. Esophageal pH monitoring. Front Gastrointest Res 1994; 22: 71-108.
86. De Boer WA, Tytgat GNJ. Review article: drug therapy for reflux ocsophagitis. Aliment Pharmacol Ther 1994; 8: 147-57.
87. Klinkenberg-Knol EC, Festen HPM, Meuwisscn SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 695-710.
88. Tytgat GNJ, Nicolai JJ, Reman FC. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990; 99: 629-34.
89. Euler AR, Murdock RH, Wilson TH, Silver MT, Parker SE, Powers L. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993; 88: 520-4.
90. Roufail W, Belsito A, Robinson M, Barish C, Rubin A. Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992; 6: 597-607.
91. Johnson NJ, Boyd EJS, Mills JG, Wood JR. Acute treatment of reflux oesophagitis. A multicentre trial to compare 150mg ranitidine b.d. with 300mg ranitidine q.d.s. Aliment Pharmacol Ther 1989; 3: 259-66.
92. Bauerfeind P, Cilluffo T, Emde C, Fimmel C, Kohler W, Gasser T, et al. Reduction of gastric acidity with ranitidine or famotidine. Early evening dosage is more effective than late evening dosage. Digestion 1987; 37: 217-22.
93. Wesdorp ICE. Famotidine in gastroesophageal reflux disease (GERD). Hepato-Gastroenterology 1992; 39(suppl 1): 24-6.
94. Simon TJ, Berlin RG, Tipping R, Gilde L. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scand J Gastroenterol 1993; 28: 375-80.
95. Sabesin SM, Berlin RG, Humphries TJ, Bradstreet DC, Walton-Bowen KL, Zaidi S. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med 1991; 151: 2394-400.
96. Robinson M, Decktor DL, Stone RC, Pevelery M, Barden P, Moyer R, et al. Famotidine (20mg) b.d. relieves gastro-oesophageal reflux symptoms in patients without erosive oesophagitis. Aliment Pharmacol Ther 1991; 5: 631-43.
97. Cloud ML, Offen WW. Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group. Dig Dis Sci 1992; 37: 865-74.
98. Quick RFP, Cooper MJ, Gleeson M, Hentschel E, Schuetze K, Kingston RD, et al. A comparison of two doses of nizatidine vs placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1990; 4: 201-11.
99. Chiba N, Gara CJ de, Burget DW, Wilkinson J, Hunt RH. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis. Gastroenterology 1993; 104: A53.
100. Robinson M, Sahba B, Avner D, Jhalas N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31.
101. Hetzel DJ, Dent J, Reed WD, Narielvala FM, MacKinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenlerology 1988; 95: 903-12.
102. Bate CM, Booth SN, Crowe JP, Hepworth-Jones B, Taylor MD, Richardson PDI. Does 40mg omeprazole daily offer additional benefit over 20mg daily in patients requiring more than 4weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993; 7: 501-7.
103. Hatlebakk JG, Berstad A, Carling L, Svedberg LE, Unge P, Ekstrom P, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224-8.
104. Mössner J, Hölscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
105. Bardhan KD, Morris P, Thompson M, Dhande DS, Hinchliffe RFC, Jones RB, et al. Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. Gut 1990; 31: 745-9.
106. Robinson M, Campbell DR, Sontag S, Sabesin SM. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995; 40: 590-7.
107. Weinbeck M. Does cisapride added to H2-receptor-blocking treatment improve healing rates in patients with esophagitis? The Ranpride Study Group. Digestion 1986; 34: A144.
108. Galmiche JP, Brandstatter G, Evreux M, Hentschel E, Kerstan E, Kratochvil P, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial. Gut 1988; 29: 675-81.
109. Dent J, Yeomans ND, MacKinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
110. Lundell L, Backman L, Ekström P, Enander LK, Falkmer S, Fausa O, Grimelius L, et al. Prevention of relapse of reflux esophagitis after endoscopic healing. The efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56.
111. Koetz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198-205.
112. Hurlimann S, Abbühl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
113. Bianchi-Porro G, Pace F, Sangaletti O, Peracchia A, Bonavina L, Vigneri S, et al. High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a 'medium-term' open study. Am J Gastroenterol 1991; 86: 1585-7.
114. Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion 1992; 51(Suppl 1): 35-42.
115. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 1991; 36: 552-7.
116. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
117. Zeitoun P, Barbier P, Cayphas JP, Isal JP, Carlsson R. Comparison of two dosage regiments of omeprazole - 10mg once daily and 20mg weekends - as prophylaxis against recurrence of reflux esophagitis. Hepatogastroenterology 1989; 36: 279-80.
118. Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994: 107: 1305-11.
119. Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PWN, Hepworth-Jones B, et al. Omeprazole 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492-8.
120. Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MWL, Shepherd NA, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623-8.
121. Lundell L, Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus. Digestion 1992; 51(Suppl 1): 49-58.
122. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377-80.
123. eConférence de consensus en réanimation et médecine d'urgence. Réan Soins Intens Méd Urg 1988; 4: 241-5.
124. Smythe MA, Zarowitz BJ. Changing perspectives of stress gastritis prophylaxis. Ann Pharmacother 1994; 28: 1073-85.
125. Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987; 106: 562-7.
126. Cook DJ, Reeve BK, Scholes LC. Histamine-2-receptor antagonists and antacids in the critically ill population. Stress ulceration versus nosocomial pneumonia. Infect Control Hosp Epidemiol 1994; 15: 437-42.
127. Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis. A meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991; 19: 942-9.
128. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases (second of two parts). N Engl J Med 1990; 323: 1749-55.
129. Prod'hom G, Leuenberger P, Koerfer J, Blum A, Chiolero R, Schaller MD, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120: 653-62.
130. Nash J, Lambert L, Deakin M. Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use. Drugs 1994; 47: 862-71.
131. Lind T, Aadland E, Eriksson S, Fernström P, Hasselgren G, Lundell L. Beneficial effects of I.V. omeprazole (OME) in patients with peptic ulcer bleeding (PUB) (abstract). Gastroenterology 1995; 108: A150.
132. Schaffalitzky de Muckadell OB, Havelund T, Marling H, Boesby S, Snel P, Vreeburg EM, et al. Omeprazole improves outcome in peptic ulcer bleeding. Gastroenterology 1995; 108: A212.
133. Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5(Suppl 1): 145-62.
134. Talley NJ. Functional dyspepsia. Should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995; 9: 107-15.
135. Jebbink HJA, Smout AJPM, Van Berge-Henegouwen GP. Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol 1993; 200(Suppl28): 8-14.
136. Müller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic of Germany. Arzneimittelforschung 1994; 44: 1130-2.
137. Gudjonsson H, Oddsson E, Björnsson S, Gunnlaugsson O, Theodors A, Jonasson TA, et al. Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study. Scand J Gastroenterol 1993; 28: 969-72.
138. Agence du Médicament. Traitement médicamenteux de l'ulcère gastrique et de l'ulcère duodénal. In: Fiches de transparence. Le bon usage du medicament. Saint Denis: Agence du Médicament. 1994; octobre: 19-21.
139. American Medical Association. Drugs used in disorders of the upper gastrointestinal tract. In: Drug Evaluations. Annual 1995.Washington: AMA, Division of Drugs and Toxicology. 1995; summer: 925-54.
140. Arakawa T, Kobayashi K, Dajani EZ. Refractory peptic ulcers. J Assoc Acad Minor Phys 1992; 3: 95-101.
141. Bardhan KD. Can the H2-receptor antagonists change the natural history of duodenal ulcer disease? Am J Gastroenterol 1994; 89: 3-6.
142. Beker JA, Bianchi-Porro G, Bigard MA, Delle Fave G, Devis G, Gouerou H, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 407-10.
143. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
144. Ben-Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: a randomized, controlled, single-blind study. Ann Intern Med 1994; 121: 568-75.
145. Bergmann JF, Hamelin B, Barbier JP. Comparaison des rapports coût-efficacité du traitement de l'œsophagite par reflux par oméprazole et ranitidine. Gastroenterol Clin Biol 1995; 19: 482-6.
146. Bianchi-Porro G, Parente F. Antacids for duodenal ulcer: current role. Scand J Gastroenterol Suppl 1990; 174: 48-53.
147. Bond CM. Guidelines for dyspepsia treatment. Pharm J 1994; 252: 228-9.
148. Bruley Des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
149. Burgess P, Larson GM, Davidson P, Brown J, Metz CA. Effect of ranitidine on intragastric pH and stress-related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci 1995; 40: 645-50.
150. Bynum TE, Koch GG. Maintenance therapy with sucralfate in duodenal ulcer. Genuine prevention or accelerated healing of ulcer recurrence? Am J Med 1991; 91(Suppl 2A): 84S-90S.
151. Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés. Les prescriptions de médicaments anti-ulcéreux. In: Evaluations dans le domaine de la santé 1991/1994. Paris: CNAMTS, Service Médical de l'Assurance Maladie Région Alsace-Moselle, 1994: 96-105.
152. Chalmers TC. Stress ulcer prophylaxis in critically ill patients: a meta-analysis. ACP J Club 1992; July/August: 15.
153. Chiverton SG, Burget DW, Hunt RH. Smoking does not impair the response to therapy in duodenal ulcer (DU) healing. Gastroenterology 1988; 97: A69.
154. Colin Jones DG. Histamine-2-receptor antagonists in gastro-oesophageal reflux. Gut 1989; 30: 1305-8.
155. Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in critically ill patient: a meta-analysis. ACPJ Club 1991; July/August: 519-27.
156. David J. Maintenance treatment with ranitidine. Am J Gastroenterol 1994; 89: 1597-8.
157. De Caestecker JS, Blackwell JN, Pryde A, Heading RC. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 1987; 28: 519-26.
158. Eriksson S, Langström G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467-75.
159. Farup PG, Larsen S, Ulshagen K, Osnes M. Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidinc and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991; 26: 1209-16.
160. Feldman M, Burton ME. Histamine-2-receptor antagonists. Standard therapy for acid-peptic diseases (first of two parts). N Engl J Med 1990; 323: 1672-80.
161. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Alternative management strategies for paients with suspected peptic ulcer disease. Ann Intern Med 1995; 123: 260-8.
162. Food and Drug Administration. Guidelines for the clinical evaluation of anti-ulcer drugs. Rockville: FDA, 1985: 25P.
163. Fraser AG. Review article. Gastro-oesophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther 1994; 8: 265-72.
164. Galmiche JP, Bruley Des Varannes S. Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 62-8.
165. Galmiche JP, Janssens J. The pathophysiology of gastro-oesophageal reflux disease: an overview. Scand J Gastroenterol 1995; 30 (suppl 211): 7-18.
166. Galmiche JP, Vallot T. Therapeutic strategy. In: Galmiche JP, Jian R, Mignon M, Ruszniewski P Eds. Non-ulcer dyspepsia: pathophysiological and therapeutic approaches. Paris: John Libbey Eurotexl, 1991: 247-64.
167. Galmiche JP. Traitement de l'œsophagite de reflux par les inhibiteurs de pompe à protons: de l'efficacité à la dépendance. Hépato-Gastro 1995; 3: 215-9.
168. Guslandi M, Ballarin E, Fanti L, Sorghi M, Tittobello A. Follow-up of endoscopic gastritis after healing with sucralfate or an H2-receptor antagonist. Scand J Gastroenterol Suppl 1992; 27: 25-7.
169. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994; 29: 618-23.
170. Hixson LJ, Kelley CL, Jones WN, Tuohy CD. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med 1992; 152: 726-32.
171. Holt S. Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases? Drugs 1994; 47: 1-11.
172. Holtmann G, Armstrong D, Goebell H, Arnold R, Classen M, Fischer M, et al. Does long-term maintenance therapy with ranitidine affect the natural course of duodenal ulcer disease? RUDER Study Group. Eur J Gastroenterol Hepatol 1993; 5: 311-7.
173. Howden CW, Castell DO, Cohen S, Freston JW, Orlando RC, Robinson M. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155: 1465-71.
174. Hui WM, Lam SK, Lok ASF, Ng MMT, Lai CL. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. Am J Med 1992; 92: 265-74.
175. Interdisciplinary Group for Ulcer Study. Six months of omeprazole 20mg daily, 20mg every other day or 40mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Digestion 1995; 56: 181-6.
176. Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole. Digestion 1992; 51(Suppl 1): 93-101.
177. Johannessen T, Petersen H, Kristensen P, Fosstvedt D, Kleveland PM, Dybdahl J, et al. Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials. Scand J Gastroenterol 1992; 27: 189-95.
178. Johnston DA, Wormsley KG. The effect of food on ranitidine-induced inhibition of nocturnal gastric secretion. Aliment Pharmacol Ther 1988; 2: 507-11.
179. Just R, Katzka DA, Castell DO. Omeprazole failure in a palient with gastroesophageal reflux disease. Ann Intern Med 1994; 121: 899.
180. Kalantzis N, Theodoropoulos G, Katsaros D, Tzivras M, Fertakis A, Archimandritis A. Ranilidine and antacids in the prevention of duodenal ulcer relapse in Greece. Hepatogastroenterology 1992; 39: 277-9.
181. Kamel P, Kahrilas PJ, Hanson DG, McMahan J, Brenic S. Prospective trial of omeprazole in the treatment of «reflux laryngitis». Gastroenterology 1992; 102: A93.
182. Kiilerich S, Rannem T, Elsborg L. Effect of intravenous infusion of omeprazole and ranitidine on Iwenty-four-hour intragastric pH in patients with a history of duodenal ulcer. Digestion 1995; 56: 25-30.
183. Koch GG, Kurata JH, Nogaway AN. Maintenance therapy of duodenal ulcer with H2-rcceptor antagonists. A re-appraisal of the meta-analysis of Palmer et al. (Letter). Aliment Pharmacol Ther 1991; 5: 441-3.
184. Kohn A, Annibale B, Delle Fave G, Levenstein S. Maintenance treatment with H2-receptor antagonists for duodenal ulcer disease: toward a rational use. Dig Dis Sci 1993; 11: 228-38.
185. Larrain A, Carrasco E, Galleguillos F, Sepulveda R, Pope CE. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 1330-5.
186. Le Rhun M, Galmiche JP. La régression de l'endobrachyoesophage est-elle possible? Gastroenterol Clin Biol 1994; 18: D17-22.
187. Lerebours E, Michel P, Hochain P, Berkelmans I. Nizatidine as maintenance treatment of duodenal ulcer. Clinical results. Scand J Gastroenterol 1994; 29 (suppl 206): 52-5.
188. Levine JS. Misoprostol and nonsteroidal anti-inflammatory drugs. A tale of effects, outcomes, and costs. Ann Intern Med 1995; 123: 309-10.
189. Li Wan Po A. H2-antagonists for the relief of dyspepsia. Pharm J 1994; 252: 84-7.
190. Marks RD, Richter JE, Rizzo J, Koehler RE, Spenney JG, Mills TP, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15.
191. Maton PN. Omeprazole. N Engl J Med 1991; 324: 965-75.
192. Meier JH, McNally PR, Freeman SR, Stocker N, Punja M, Spaulding HS. Does omeprazole (Pri-Losec) improve asthma in patients with gastroesophageal reflux. A double blind crossover study. Gastroenterology 1992; 102: A935.
193. Merki HS, Halter F, Wilder-Smith C, Allemann P, Witzel L, Kempf M, et al. Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients. Gut 1990; 31: 148-50.
194. Office of Technology Assessment. The implications of cost-effectiveness analysis of medical technology. Case study #11. Benefit-and-cost analysis of medical interventions: the case of cimetidine and peptic ulcer disease. Washington: OTA, 1981; September: 65P.
195. Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers. Med Care 1990; 28: 834-52.
196. Pingleton SK. Prophylaxis of stress ulcer bleeding: a meta-analysis. ACP J Club 1992; Jan/Feb: 9.
197. Poynard T, Pignon JP. Duodenal ulcer. Analyses of 293 randomized clinical trials. Montrouge: John Libbey Eurotext,1989.
198. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5.
199. Rampal P, Martin C, Marquis P, Ware JE, Bonfils S. A quality of life study in five hundred and eighty-one duodenal ulcer patients. Maintenance versus intermittent treatment with nizatidine. Scand J Gastroenterol 1994; 29 (suppl 206): 44-51.
200. Rodney WM. Peptic disease syndrome: should we treat H. pylori? Am Fam Phys 1993; 47: 742-4.
201. Rösch W. Chronic functional dyspepsia. Short- and medium-term outcome of a therapeutic trial with cisapride. Clin Ther 1994; 16: 437-45.
202. Sewing KF. Efficacy of low-dose antacids in the treatment of peptic ulcers: pharmacological explanation? J Clin Gastroenterol 1991; 13(Suppl 1): S134-8.
203. Sobhani I, Chastang C, dc Korwin J-D, Lamouliatte H, Megraud F, Guerre J, et al. Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial. Gastroenterol Clin Biol 1995; 19: 252-8.
204. Solcia E, Villani L, Fiocca R, Luinetti O. Boldorini R, Trespi E, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 29 (suppl 201): 28-34.
205. Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584-9.
206. Trespi E, Broglia F, Villani L, Luinetti O, Fiocca R, Solcia E. Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication. Scand J Gastroenterol 1994; 29: 884-8.
207. Veldhuyzen Van Zanten SJO. A systematic overview (meta-analysis) of outcome measures in Helicobacter pylori gastritis trials and functional dyspepsia. Scand J Gastroenterol 1993; 28 (suppl 201): 40-3.
208. Walan A, Eriksson S. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer. Scand J Gastroenterol 1994; 29 (suppl 201): 91-7.
209. Walt RP, Langman MJS. Antacids and ulcer healing. A review of the evidence. Drugs 1991; 42: 205-12.
210. Wormsley KG. Maintenance therapy for peptic ulcer disease. Aliment Pharmacol Ther 1991; 5(Suppl 1): 37-47.
211. Wright JM, Sarich TC, Waldum HL, Brenna E, Freston JM, Klinkenberg-Knol E, et al. Omeprazole therapy in resistant reflux disease. Ann Intern Med 1995; 122: 236.